Endonovo Therapeutics (ENDV) EPS (Basic) (2016 - 2023)
Endonovo Therapeutics has reported EPS (Basic) over the past 12 years, most recently at -$0.0 for Q3 2023.
- Quarterly results put EPS (Basic) at -$0.0 for Q3 2023, up 59.38% from a year ago — trailing twelve months through Sep 2023 was -$0.05 (up 41.95% YoY), and the annual figure for FY2022 was -$0.13, down 160.0%.
- EPS (Basic) for Q3 2023 was -$0.0 at Endonovo Therapeutics, down from $0.01 in the prior quarter.
- Over the last five years, EPS (Basic) for ENDV hit a ceiling of $1.47 in Q1 2020 and a floor of -$13.57 in Q2 2019.
- Median EPS (Basic) over the past 5 years was -$0.03 (2022), compared with a mean of -$1.33.
- Biggest five-year swings in EPS (Basic): crashed 377369.5% in 2019 and later skyrocketed 200.0% in 2023.
- Endonovo Therapeutics' EPS (Basic) stood at -$5.83 in 2019, then surged by 96.57% to -$0.2 in 2020, then surged by 125.0% to $0.05 in 2021, then tumbled by 260.0% to -$0.08 in 2022, then skyrocketed by 97.5% to -$0.0 in 2023.
- The last three reported values for EPS (Basic) were -$0.0 (Q3 2023), $0.01 (Q2 2023), and $0.03 (Q1 2023) per Business Quant data.